Novavax Inc (NVAX): Gregory M Glenn , President, R&D of Novavax Inc purchased 1,000 shares on Sep 21, 2016. The Insider buying transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.65 per share for a total value of $1,649.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 21, 2016, Gail Boudreaux (director) purchased 100,000 shares at $1.45 per share price.On Aug 2, 2016, Barclay A Phillips (CFO) purchased 422 shares at $4.29 per share price.Also, On Jun 7, 2016, Gary C Evans (director) sold 18,998 shares at $6.50 per share price.On Feb 1, 2016, John Trizzino (SVP, Commercial Operations) purchased 5,855 shares at $3.63 per share price.
Shares of Novavax (NVAX) ended Tuesday, Sep 21, 2016 session in red amid volatile trading. The shares closed down -0.03 points or -2.01% at $1.46 with 3,03,39,912 shares getting traded. Post opening the session at $1.49, the shares hit an intraday low of $1.39 and an intraday high of $1.52 and the price vacillated in this range throughout the day. The company has a market cap of $396 M and the number of outstanding shares has been calculated to be 27,11,87,650 shares. The 52-week high of Novavax is $10.7 and the 52-week low is $1.16.
Company has been under the radar of several Street Analysts.Novavax is Reiterated by Chardan Capital Markets to Neutral while Lowering the Price Target of the company shares to $ 1.50 from a previous price target of $5.75 . The Rating was issued on Sep 20, 2016.Novavax is Downgraded by Citigroup to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Sep 16, 2016.Novavax is Downgraded by Wedbush to Neutral while Lowering the Price Target of the company shares to $ 2 from a previous price target of $14 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Sep 16, 2016.Novavax is Downgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Sep 16, 2016.Novavax is Downgraded by JP Morgan to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Sep 16, 2016.
Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).